Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 02, 2008. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction notification rather than comprehensive financial performance.
Material Changes
A re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan resulted in an increase in the notional allocation of Ordinary share ADRs for Dr R G Greig. This transaction occurred on 28 December 2007 at a price of $50.75 per ADR share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: 28 December 2007
- Notification Date: 31 December 2007
- Individual Involved: Dr R G Greig
- Security Type: GSK Ordinary Share ADRs
- Transaction Price: $50.75 per ADR
- Quantity: 10 ADRs
- Context: Increase in notional allocation due to plan re-valuation